Abstract
A 72-year-old woman having abdominal pain and high fever was diagnosed with KRAS wild-type sigmoid colon cancer, invading the urinary bladder and uterus with a pelvic abscess. Considering the difficulty of curative resection, we first performed sigmoid colostomy and abscess drainage. Remarkable tumor regression was indicated by CT and colonoscopy after 1 course of FOLFIRI and 5 courses of FOLFIRI+panitumumab. Following an additional 2 courses of panitumumab, sigmoidectomy and partialcystectomy were performed. Six courses of FOLFIRI+panitumumab were administered postoperatively and no recurrence has been observed for 7 months. FOLFIRI+panitumumab may be an effective preoperative chemotherapy for patients with KRAS wild-type locally advanced colon cancer.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Middle Aged
-
Neoadjuvant Therapy*
-
Neoplasm Invasiveness
-
Panitumumab
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins p21(ras)
-
Sigmoid Neoplasms / drug therapy*
-
Sigmoid Neoplasms / genetics
-
Sigmoid Neoplasms / surgery
-
ras Proteins / genetics
Substances
-
Antibodies, Monoclonal
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Panitumumab
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins
-
Leucovorin
-
Fluorouracil
-
Camptothecin